Key facts
- This page summarizes Roivant Sciences Ltd.'s Form 4 filing for Arbutus Biopharma Corp (ABUS).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 Oct 2021, 17:14.
Roivant Sciences Ltd. - 18 Oct 2021 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- ABUS
- Reported as of
- 18 Oct 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 Oct 2021, 17:14:24 UTC
- Prior SEC filing
- 02 Aug 2021
- Next SEC filing
- 07 Oct 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matt Maisak, Authorized Signatory
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Roivant Sciences Ltd. filed Form 4 for Arbutus Biopharma Corp (ABUS) on 20 Oct 2021.
Change
- Previous filing in this sequence was filed on 02 Aug 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABUS
transaction
Common shares, without par value
Conversion of derivative security
- Transaction value
- Shares
- +22,833,922
- Change %
- +143%
- Price
- Shares after
- 38,847,462
- Date
- 18 Oct 2021
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ABUS
transaction
Derivative
Series A participating convertible preferred shares
Conversion of derivative security
- Transaction value
- Shares
- -1,164,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 18 Oct 2021
- Ownership
- Direct
- Underlying class
- Common shares
- Underlying amount
- 1,164,000
- Exercise price
- $7.13
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On October 18, 2021, 1,164,000 Series A participating convertible preferred shares of the Issuer held by the Reporting Person, which were previously acquired by the Reporting Person in two tranches in October 2017 and January 2018, mandatorily converted into 22,833,922 common shares, without par value (the "Common Shares"), of the Issuer, in accordance with their terms.
Footnote F2
Includes 16,013,540 Common Shares that were previously acquired by the Reporting Person in 2015.